GW Pharmaceuticals plc: 07/12/2015 GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2015 Financial Results and Operational Progress

Tickers: GWPH
ea287b12-f173-4425-87e5-2af0d943f467.pdf

December 7, 2015

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Wal-Mart Stores, Inc.

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2015 Financial Results and Operational Progress


- Three Phase 3 Epidiolex Clinical Trials Fully Recruited Above Target Sample Size - on Track for Initial Data in Q1 2016 -


- Significant Clinical Activity in Multiple Cannabinoid Pipeline Programs -


- Conference Call Today at 4:30 p.m. EST, 9:30 p.m. GMT -


LONDON, Dec. 7, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP), ('GW,' 'the Company'

or 'the Group'), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the fourth quarter and twelve months ended 30 September 2015.


'This last year has seen GW maintain a rapid pace in the progress of our pediatric epilepsy research program, including the start and completion of recruitment of multiple Phase 3 trials for Epidiolex, and the expansion of our expanded access program which has continued to yield promising safety and efficacy data,' stated Justin Gover, GW's Chief Executive Officer. 'We expect to carry this momentum through 2016 with top-line data from four Epidiolex pivotal trials, our first NDA filing, build-out of our

  1. commercial organization, and ongoing data read-outs from a number of clinical pipeline programs.'


    2015 HIGHLIGHTS


    • Epidiolex® (CBD) childhood epilepsy program:

      O Company sponsored Phase 3 development programs in Dravet syndrome and Lennox-Gastaut syndrome

      • First Phase 3 Dravet syndrome trial fully enrolled above original target sample size (120 randomized) data expected Q1 2016

      • First LGS Phase 3 trial fully enrolled above original target sample size (171 randomized). Data expected Q2 2016

      • Second LGS Phase 3 trial fully enrolled above original target sample size. ( > 210 expected to randomize). Data expected Q2 2016

      • Second Phase 3 Dravet syndrome trial ongoing. Data expected mid 2016

      • NDA submission with FDA expected Q4 2016

      • Phase 3 Tuberous Sclerosis Complex trial expected to commence Q1 2016

      • Additional clinical development for Epidiolex beyond initial three indications expected to commence in H2 2016

        O Expanded access program:

      • Separate data update announcement issued today at the American Epilepsy Society December 2015 Annual Meeting

      • Approximately 350 children on treatment at 32 U.S. clinical sites

      • Over 850 children authorized for treatment by FDA under Expanded Access Treatment INDs and 6 U.S. State programs

        O Strategic agreement with Government of New South Wales in Australia to conduct Epidiolex and CBDV clinical trials

        O CBD and CBDV patent portfolio strengthened

    • Advanced clinical programs in multiple cannabinoid pipeline product candidates:

      O Phase 2a CBD schizophrenia study data shows positive proof-of-concept with a reassuring safety profile

      O Phase 2 CBDV epilepsy study in adults underway with data expected H2 2016

      O Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) IV CBD Phase 1 clinical program expected to commence in H1 2016

      • Orphan Drug and Fast Track Designations granted from FDA and EMA

        O Clinical trials within the field of autism spectrum disorders expected to commence in H2 2016

        O Phase 1b/2a study for the treatment of Recurrent Glioblastoma Multiforme (GBM) fully enrolled with data expected in mid-2016

      • Orphan Drug Designation granted from FDA

        O Phase 2 study in type-2 diabetes fully enrolled with data expected mid 2016

        O Phase 2 study of Sativex in spasticity due to cerebral palsy ongoing with data expected mid 2016

    • Pre-clinical progress addressing a number of areas of unmet need including autism spectrum disorders, duchenne muscular dystrophy, glioma, ovarian and pancreatic cancers, and chemotherapy-induced cachexia

    • U.S. operations established in Carlsbad, California

      O GW's CEO, Justin Gover, relocates to the U.S.

      O Seasoned industry executive Julian Gangolli appointed as President, North America

      O Epilepsy specialist team build-out underway


      FINANCIAL HIGHLIGHTS


    • Balance sheet further strengthened with successful NASDAQ follow-on offering raising net proceeds after expenses of

      £127.5 million ($193.3 million)


    • Revenue for the twelve months ended 30 September 2015 of £28.5 million ($43.2 million) compared to £30.0 million for the twelve months ended 30 September 2014


    • Loss for the twelve months ended 30 September 2015 of £44.6 million ($67.4 million) compared to £14.7 million for the twelve months ended 30 September 2014


    • Cash and cash equivalents at 30 September 2015 of £234.9 million ($355.3 million) compared to £164.5 million as at 30 September 2014


Conference Call and Webcast Information


GW Pharmaceuticals will host a conference call and webcast to discuss the 2015 fourth quarter and year-end financial results today at 4:30 p.m. EST / 9:30 p.m. GMT. To participate in the conference call, please dial 877-407-8133 (toll free from the U.S. and Canada), or 0800-756-3429 (toll free from the UK) or 201-689-8040 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company's website at http://www.gwpharm.com. A replay of the call will also be available through the GW website shortly after the call and will remain available for 90 days. Replay Numbers: (toll free):1-877-660-6853, (international):1-201-612-7415. For both dial-in numbers please use conference ID #13626013.


Enquiries:


GW Pharmaceuticals plc

Stephen Schultz, VP Investor Relations 401 500 6570


FTI Consulting (Media Enquiries)

Ben Atwell / Simon Conway + 44 20 3727 1000


GW Pharmaceuticals plc

Condensed consolidated income statement Three months ended 30 September 2015


Three months Three months Three months

ended

ended

ended

30 September 30 September 30 September

2015

$000's

2015

£000's

2014

£000's

Revenue 8,463 5,595 7,419

Cost of sales (1,033) (683) (419)

Research and development expenditure (38,510) (25,457) (12,269)

Sales, general and administrative expenses (7,545) (4,988) (1,844)

Net foreign exchange gain 10,399 6,874 5,411


Operating loss (28,226) (18,659) (1,702)

Interest income 125 83 50


Interest expense

(22)

(15)

(2)


Loss before tax


(28,123)


(18,591)


(1,654)

Tax benefit

9,618

6,358

1,936


(Loss)/profit for the period


(18,505)


(12,233)


282


(Loss)/profit per share - basic and diluted


(7.1c)


(4.7p)


0.1p


All activities relate to continuing operations.


GW Pharmaceuticals plc

Condensed consolidated income statement

Year ended 30 September 2015


Year ended 30 September

2015

$000's


Year ended 30 September

2015

£000's


Year ended 30 September

2014

£000's

Revenue

43,172

28,540

30,045

Cost of sales

(3,960)

(2,618)

(2,060)

Research and development expenditure

(116,153)

(76,785)

(43,475)

Sales, general and administrative expenses

(19,013)

(12,569)

(7,337)

Net foreign exchange gain

9,382

6,202

3,188


Operating loss


(86,572)


(57,230)


(19,639)

Interest income

369

244

130

Interest expense

(113)

(75)

(61)


Loss before tax


(86,316)


(57,061)


(19,570)

Tax benefit

18,906

12,498

4,911


Loss for the year


(67,410)


(44,563)


(14,659)


Loss per share - basic and diluted


(27.4)c


(18.1)p


(7.0)p


All activities relate to continuing operations.


Condensed consolidated statement of comprehensive loss For the year ended 30 September 2015


Year ended

Year ended

30 September 30 September

2015

£000's

2014

£000's

Loss for the year (44,563) (14,659)

Items that may be reclassified subsequently to profit or loss

Exchange differences on translation of foreign operations (71) (2)

Other comprehensive loss for the year (71) (2)

Total comprehensive loss for the year (44,634) (14,661)


GW Pharmaceuticals plc

Condensed consolidated statement of changes in equity Year ended 30 September 2015


Called-up

Share

share premium

Other Accumulated

Total

capital

account reserves

deficit

Equity

£000's

£000's

£000's

£000's

£000's

Balance at 1 October 2013 178 84,005 20,184 (68,965) 35,402

Issue of share capital 51 127,315 -- -- 127,366

Expense of new equity issue -- (1,067) -- -- (1,067)

Exercise of share options 4 5,014 -- -- 5,018

Exercise of warrants 4 5,284 (922) 922 5,288

Share-based payment transactions -- -- -- 1,238 1,238

Loss for the period -- -- -- (14,659) (14,659)

Other comprehensive expense -- -- (2) -- (2)


Balance at 30 September 2014 237 220,551 19,260 (81,464) 158,584


Balance at 1 October 2014 237 220,551 19,260 (81,464) 158,584

Issue of share capital (note 12) 22 127,812 -- -- 127,834

Expense of new equity issue -- (271) -- -- (271)

Exercise of share options 2 1,183 -- -- 1,185

Share-based payment transactions -- -- -- 2,488 2,488

Loss for the year -- -- -- (44,563) (44,563) Deferred tax attributable to unrealized share option gains -- -- -- 84 84

Other comprehensive expense -- -- (71) -- (71)


Balance at 30 September 2015 261 349,275 19,189 (123,455) 245,270


GW Pharmaceuticals plc

Condensed consolidated balance sheet As at 30 September 2015


As at 30

As at 30

As at 30

September September September



Non-current assets

2015


$000's

2015


£000's

2014


£000's

Intangible assets - goodwill

7,881

5,210

5,210

Other intangible assets

371

245

--

Property, plant and equipment

43,464

28,733

11,639

Deferred tax asset

632

418

277


52,348


34,606


17,126

distributed by

This content was issued by GW Pharmaceuticals plc on the 2015-12-07 and was initially posted on www.gwpharm.com. It was distributed, unedited and unaltered, by noodls on 2015-12-07 21:14:25 UTC. The original issuer is solely responsible for the accuracy of the information contained therein.